|
| 吡嗪酰胺抗结核化疗致高尿酸血症流行病学调查 |
| Epideminological Study of Hyperuricemia Induced by Pyrazinamide for Patients in Antituberculous Therapy |
| 投稿时间：2011-10-14 修订日期：2011-12-23 |
| DOI： |
| 中文关键词: 吡嗪酰胺 结核病 高尿酸血症 流行病学 |
| 英文关键词:Pyrazinamide Tuberculosis Hyperuricemia Epideminological study |
| 基金项目: |
|
| 摘要点击次数: 1469 |
| 全文下载次数: 2020 |
| 中文摘要: |
| 摘 要 目的：对抗结核治疗方案中吡嗪酰胺致高尿酸血症发生率进行流行病学调查，为临床用药和尿酸检测提供参考。方法：回顾性调查我院2003～2010年诊断为原发或继发性肺结核和结核性胸膜炎的住院患者，根据是否使用吡嗪酰胺，将病例分为暴露组（HRZE）134例和非暴露组（HRE）40例，比较两组间高尿酸血症发生率。结果：我院结核病患者使用吡嗪酰胺比例为86.2%，暴露组和非暴露组高尿酸血症发生率分别为79.1%和10.0%。平均用药11 d后，暴露组血尿酸均值从（275.3±77.2）μmol·L-1升高到（562.9±160.0）μmol·L-1。与非暴露组比较，暴露组发生高尿酸血症的相对危险度(RR)为7.91（95%CI=4.74～13.19），两组高尿酸血症发生率差异有统计学意义（P＜0.01）。结论：使用吡嗪酰胺致高尿酸血症发生率较高，临床应定期监测血尿酸浓度。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate hyperuricemia induced by pyrazinamide for patients in antituberculous therapy for reference to clinical medication and uric acid detection.Method:All tuberculous patients hospitalized during 2003 to 2010 were divided into an exposed group (HRZE，n=134) and non exposed group (HRE，n=40), and hyperuricemia was analyzed in the two groups.Result:Pyrazinamide was prescribed to 86% patients in antituberculous therapy, and the percentage of hyperuricemia in the exposed group and non exposed group were 79.1% and 10% respectively. The uric acid in the exposed group increased from （275.3±77.2）μmol·L-1(baseline value) to（562.9±160.0）μmo·L-1 after 11 day’s therapy. The relative risk(RR) of hyperuricemia in the exposed group was 7.91（95%CI=4.74-13.19）. Conclusion:Patients taking pyrazinamide in antituberculous therapy had a higher proportion of hyperuricemia, and doctors should monitor uric acid regularly. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
